Supplementary Online Content

Goyal G, Lau KW, Wang X, et al. The COVID-19 pandemic and in-person visit rate disruptions among patients with hematologic neoplasms in the US in 2020 to 2021. *JAMA Netw Open*. 2023;6(6):e2316642. doi:10.1001/jamanetworkopen.2023.16642

This supplementary material has been provided by the authors to give readers additional information about their work.

eMethods. (S)ARIMA Models

ARIMA models use a linear combination of lagged observations (autoregression) and lagged errors (moving average) to forecast future observations. They are presented as ARIMA(*p,d,q*), where p is the order of autoregression (number of lagged observations), d is the order of differencing, and q is the moving average order (number of lagged errors) and are modelled as:

$$(1 - B)^d \widehat{Y_t} = \alpha + \frac{\theta(B)}{\phi(B)}\varepsilon_t$$

Where $\widehat{Y_t}$ is the forecasted monthly standardized 30 patient-day rates of in-person treatment visits, *B* is a backshift operator (e.g. $BY_t = Y_{t-1}$), and α is the constant. The autoregressive (AR) operator, $\varphi(B)$, is equal to $1 - \varphi_1 B^1 - \varphi_2 B^2 \ldots - \varphi_p B^p$ with order *p*; the moving average (MA) operator, $\Theta(B)$, is equal to $1 - \Theta_1 B^1 - \Theta_2 B^2 \ldots - \Theta_q B^q$ with order *q*; ε_t is the error term.

Each (S)ARIMA model was built using the following steps: First, since ARIMA models must fit to stationary data with constant mean, variance, and autocorrelation over time, stationarity of the time series was determined using augmented Dickey-Fuller tests. Orders of differencing increased incrementally until stationarity was achieved. Second, the combination of AR and MA orders that minimize the Akaike Information Criterion were determined using autocorrelation (ACF) and partial autocorrelation (PACF) plots, respectively. Third, goodness-of-fit was tested using the Ljung-Box Q test, which tests whether a time series' autocorrelations are different from zero. A non-significant Q statistic indicated that the data is independently distributed and thus, the model was a good fit. All model parameters selected are outlined in eTable 2 and Ljung-Box Q test results are found in eTable 3.

Seasonal parameters (SARIMA) were utilized if the data exhibited seasonal or cyclical trends (i.e. spikes in ACF plots that occur at regular cadences), presented as ARIMA$(p,d,q)(P,D,Q)_m$. P is the seasonal order of autoregression, D is the seasonal order of differencing, Q is the seasonal moving average order, and m is the number of periods in a season, which was set to 12 as monthly data was used.

eFigure. Patient Selection Diagram for the Cohort With Hematologic Malignancies



Footnotes:

1. AML patients met the following criteria: (1) Has an ICD diagnosis code of Acute Myeloid Leukemia (AML) [ICD 9: 205.0x, 205.9x, 206.0x, 207.0x, 207.2x; ICD 10: C92.0x, C92.4x, C92.5x, C92.6x, C92.9x, C92.Ax, C93.0x, C94.0x, C94.2x, C94.4x]; (2) Has at least two documented clinical visits, on different days, occurring on or after January 1, 2011; (3) Included in probabilistic sample of patients queued for confirmation of AML diagnosis via abstraction; (4) Has evidence of AML with an initial diagnosis date on or after January 1, 2014
2. CLL patients met the following criteria: (1) Has an ICD diagnosis code of Chronic Lymphocytic Leukemia (CLL) [ICD-9: 204.1x or ICD-10: C91.1x, C83.0x]; (2) Has at least two documented clinical visits, on different days, occurring on or after January 1, 2011; (3) Has at least one order for an antineoplastic occurring on or after January 1, 2011; (4) Included in probabilistic sample of patients queued for confirmation of CLL diagnosis via abstraction; (5) Has physician documentation of CLL and evidence in unstructured documents of having been treated specifically for CLL
3. DLBCL patients met the following criteria: (1) Has an ICD diagnosis code of Non-Hodgkin's Lymphoma (NHL) [ICD 9: 200x, 202x; ICD 10: C82x, C83x, C84x, C85x, C86x, C88x, C96x]; (2) Has at least two documented clinical visits, on different days, occurring on or after January 1, 2011; (3) Included in probabilistic sample of patients queued for confirmation of DLBCL diagnosis via abstraction; (4) Has evidence of DLBCL with an initial diagnosis date on or after January 1, 2011
4. FL patients met the following criteria: (1) Has an ICD diagnosis code of NHL; (2) Has at least two documented clinical visits, on different days, occurring on or after January 1, 2011; (3) Included in probabilistic sample of patients queued for confirmation of FL diagnosis via abstraction; (4) Has evidence of FL with an initial diagnosis date on or after January 1, 2011
5. MCL patients met the following criteria: (1) Has an ICD diagnosis code of NHL; (2) Has at least two documented clinical visits, on different days, occurring on or after January 1, 2011; (3) Included in probabilistic sample of patients queued for confirmation of MCL diagnosis via abstraction; (4) Has evidence of MCL with an initial diagnosis date on or after January 1, 2011
6. MM patients met the following criteria: (1) Has an ICD diagnosis code of Multiple Myeloma (MM) [ICD-9 203.0x or ICD-10 C90.0x, C90]; (2) Has at least two documented clinical visits, on different days, occurring on or after January 1, 2011; (3) Included in probabilistic sample of patients queued for confirmation of MM diagnosis via abstraction; (4) Has evidence of MM with an initial diagnosis date on or after January 1, 2011
7. The study period ran from March 1, 2016 to February 28, 2021.

eTable 1. Regimen Classification Based on National Comprehensive Cancer Network (NCCN) Guidelines as of April 2021, and Also by Consensus of the Authorship Team

Type 1 = outpatient oral regimens (OralTx)
Type 2 = outpatient infusional regimens (OutPtTx)
Type 3 = inpatient infusional regimens (InPtTx)

Disease	Drug name	Drug name(s)	Type
For all diseases (if applicable to disease and FDA indicated by April 2021)			
	Autologous transplant		3
	Allogeneic transplant		3
	CAR T-cell therapy		3
	Clinical study drug		NA
AML			
AML	Azacitidine	Azacitidine	3
AML	Enasidenib	Enasidenib Mesylate	1
AML	Gilteritinib	Gilteritinib	1 (3 if with 7+3)
AML	Glasdegib	Glasdegib	1
AML	Hydroxyurea	Hydroxyurea	1

AML	Ivosidenib	Ivosidenib	1
AML	Lenalidomide	Lenalidomide	1
AML	Midostaurin	Midostaurin	1 (3 if with 7+3)
AML	Sorafenib	Sorafenib	1
AML	Venetoclax	Venetoclax	1 (3 if with azacitadine)
AML	Tretinoin	Tretinoin	3
AML	7+3	7+3 Not Otherwise Specified	3
AML	Vyxeos	Daunorubicin OR Daunorubicin/Cytarabine Liposomal	3
AML	ATO	Arsenic	3
AML	ATRA	Tretinoin	3
AML	Decitabine	Decitabine	3
AML	HiDAC	Cytarabine	3
AML	LDAC	Cytarabine	3
AML	CLAG	Cladribine, Cytarabine, Mitoxantrone	3
AML	FLAG	Cytarabine, Fludarabine	3
AML	GCLAC	Clofarabine, Cytarabine	3
AML	MEC	Mitoxantrone, Etoposide, Cytarabine	3
AML	Gemtuzumab Ozogamicin	Gemtuzumab Ozogamicin	3

AML	Idarubicin	Idarubicin	3
DLBCL			
DLBCL	Ibrutinib	Ibrutinib	1
DLBCL	Lenalidomide + R	Lenalidomide, Rituximab	2
DLBCL	Idelalisib	Idelalisib	1
DLBCL	Temozolomide + Methotrexate	Temozolomide, Methotrexate	3
DLBCL	Duvelisib	Duvelisib	1
DLBCL	Selinexor	Selinexor	1
DLBCL	Tazemetostat	Tazemetostat	1
DLBCL	Acalabrutinib	Acalabrutinib	1
DLBCL	RCHOP	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine	2
DLBCL	RCVP	Rituximab, Cyclophosphamide, Vincristine	2
DLBCL	BR	Bendamustine, Rituximab	2
DLBCL	Pola-BR	Polatuzumab, Bendamustine, Rituximab	2
DLBCL	Pola-R	Polatuzumab, Rituximab	2

DLBCL	REPOCH	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Etoposide	3
DLBCL	RICE	Rituximab, Ifos-famide, Carbo-platin, Etopo-side	3
DLBCL	RGemOx	Rituximab, Gemcitabine, and Oxaliplatin	2
DLBCL	RGCVP	Rituximab, Gemcitabine, Cyclophosphamide, Vincristine	2
DLBCL	RESHAP	Rituximab, Etoposide, Cytarabine, Cisplatin	3
DLBCL	RDHAP	Rituximab, Dexamethasone, Cytarabine, Cisplatin	3
DLBCL	RCEPP(B)	Rituximab, Cyclophosphamide, Etoposide, Procarbazine, Bleomycin	2
DLBCL	RCEPP	Rituximab, Cyclophosphamide, Etoposide, Procarbazine	2
DLBCL	RCEOP	Rituximab, Cyclophosphamide, Etoposide, Vincristine	2
DLBCL	High-dose MTX (systemic)	Methotrexate, Leucovorin	3
DLBCL	Cytarabine +/- R OR R-MT	Cytarabine with or without Rituximab OR Rituximab, Methotrexate	3
DLBCL	R Hyper CVAD	Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Cytarabine	3
DLBCL	Copanlisib	Copanlisib	2
DLBCL	Tafasitamab	Usually only in combination with Lenalidomide	2
DLBCL	Ofatumumab	Only in combination with other drugs like chemos (do not count if monotherapy)	2

DLBCL	Gemcitabine, Oxaliplatin, Rituximab	Gemcitabine, Oxaliplatin, Rituximab or another anti-CD20	2
DLBCL	Obinutuzumab	Only in combination with other drugs like chemos (do not count if monotherapy)	2
DLBCL	Pembrolizumab	Monotherapy or in combination with other drugs	2
DLBCL	Axicabtagene Ciloleucel	Axicabtagene Ciloleucel	3
DLBCL	Tisagenlecleucel	Tisagenlecleucel	3
DLBCL	Bortezomib + Lenalidomide	Bortezomib, Lenalidomide	2
DLBCL	Cyclo	Cyclophosphamide monotherapy	2
DLBCL	Cyclo + Doxo	Cyclophosphamide, Doxorubicin	2
DLBCL	Cyclo + Fluda + Mesna	Cyclophosphamide, Fludarabine, Mesna	2
DLBCL	Cyclo + Mesna	Cyclophosphamide, Mesna	2
FL			
FL	Duvelisib	Duvelisib	1
FL	Ibrutinib	Ibrutinib	1
FL	Idelalisib	Idelalisib	1 (2 if + R or G)

FL	Lenalidomide	Lenalidomide	1 (2 if + R or G)
FL	Selinexor	Selinexor	
FL	Tazemetostat	Tazemetostat	1
FL	Acalabrutinib	Acalabrutinib	1
FL	RCHOP	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine	2
FL	RCVP	Rituximab, Cyclophosphamide, Vincristine	2
FL	BR or BG	Bendamustine, Rituximab OR Bendamustine, Obinutuzumab	2
FL	REPOCH	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Etoposide	3
FL	RICE	Rituximab, Ifos-famide, Carbo-platin, Etopo-side	3
FL	RGemOx	Rituximab, Gemcitabine, and Oxaliplatin	2
FL	RGDP	Rituximab, Gemcitabine, Cisplatin OR Carboplatin	2
FL	RGCVP	Rituximab, Gemcitabine, Cyclophosphamide, Vincristine	2
FL	RESHAP	Rituximab, Etoposide, Cytarabine, Cisplatin	3
FL	RDHAP	Rituximab, Dexamethasone, Cytarabine, Cisplatin	3
FL	RCEPP(B)	Rituximab, Cyclophosphamide, Etoposide, Procarbazine, Bleomycin	2
FL	RCEPP	Rituximab, Cyclophosphamide, Etoposide,	2

		Procarbazine	
FL	RCEOP	Rituximab, Cyclophosphamide, Etoposide, Vincristine	2
FL	High-dose MTX (systemic)	Methotrexate, Leucovorin	3
FL	RHyperCVAD	Rituximab, Cyclophosphamide, Vincristine, Doxorubicin	3
FL	Cyclophosphamide	Cyclophosphamide	2
FL	Fludarabine + R	Fludarabine, Rituximab	2
FL	Copanlisib	Copanlisib	1
FL	Ibritumomab	Ibritumomab (both mono and in combo)	2
FL	Oftaumumab	Oftaumumab (both mono and in combo)	2
FL	Obinutuzumab	Obinutuzumab (only mono)	2
FL	Rituximab	Rituximab (both mono and in combo)	2
FL	Axicabtagene Ciloleucel	Axicabtagene Ciloleucel	3
FL	Tisagenlecleucel	Tisagenlecleucel	3
CLL			
CLL	Acalabrutinib	Acalabrutinib monotherapy OR Acalabrutinib, Obinutuzumab (G)	1 (2 if with G)
CLL	Chlorambucil	Chlorambucil monotherapy OR Chlorambucil, Rituximab OR Chlorambucil, Obinutuzumab (G)	1 (2 if with G or R)

CLL	Duvelisib	Duvelisib	1
CLL	Ibrutinib	Ibrutinib	1
CLL	Lenalidomide	Lenalidomide monotherapy OR Lenalidomide, Rituximab	1 (2 if with rituximab)
CLL	Venetoclax	Venetoclax monotherapy OR Venetoclax, Rituximab OR Venetoclax, Obinutuzumab (G)	1 (2 if with rituixmab)
CLL	Zanubrutinib	Zanubrutinib	1
CLL	FCR	Fludarabine, Cyclophosphamide, Rituximab	2
CLL	BR	Bendamustine, Rituximab	2
CLL	Pentostatin	Pentostatin (mono or in combo)	2
CLL	Fludarabine	Fludarabine (mono or in combo)	2
CLL	Rituximab	Rituximab (mono or in combo)	2
CLL	Ofatumumab	Ofatumumab (mono or in combo)	2
CLL	Obinutuzumab	Obinutuzumab (mono or in combo)	2
CLL	Alemtuzumab	Alemtuzumab	2
	Copanlisib	Copanlisib	2
CLL	PI3K + Anti CD20	(Idelalisib OR Duvelisib) AND (Rituximab OR Ofatumumab OR Obinutuzumab)	2
CLL	PI3K monotherapy	Idelalisib OR Duvelisib monotherapy	1
CLL	Anti-CD20 based	Rituximab OR Ofatumumab OR Obinutuzumab	2

	monotherapy	monotherapy	
CLL	BCL-2 based therapy	Venetoclax monotherapy or in combo with any other drug	1 (2 if with G or R)
CLL	BTK inhibitor monotherapy	Ibrutinib OR Acalabrutinib monotherapy or in combo with any other drug)	1
MCL			
MCL	Acalabrutinib	Acalabrutinib	1
MCL	Ibrutinib	Ibrutinib	1
MCL	Lenalidomide	Lenalidomide OR Lenalidomide, Rituximab	1 (2 if + R)
MCL	Procarbazine	Procarbazine *only* in combination with other drugs (Cyclophosphamide, Etoposide, Rituximab, OR Ifosfamide); not mono	1,2, or 3 depending on combo
MCL	Venetoclax	Venetoclax monotherapy OR Venetoclax + Rituximab	1 (2 if + R)
MCL	Zanubrutinib	Zanubrutinib	1
MCL	RCHOP	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine	2
MCL	BR	Bendamustine, Rituximab	2
MCL	RDHAP	Rituximab, Cytarabine, Cisplatin	3
MCL	RHyperCVAD	Rituximab, Cyclophosphamide, Vincristine, Doxorubicin	3
MCL	NORDIC Regimen	Cyclophosphamide, Cytarabine, Doxorubicin, Rituximab, Vincristine	3

MCL	VR-CAP	Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin	2
MCL	RBAC (BR/CR)	Rituximab, Bendamustine, Cytarabine OR Bendamustine, Rituximab OR Cytarabine, Rituximab	2 (BR) 3(CR)
MCL	RCEPP	Rituximab, Cyclophosphamide, Etoposide, Procarbazine	2
MM			
MM	Thalidomide	Thalidomide	1
MM	Panobinostat	Panobinostat	1
MM	Ixazomib	Ixazomib	1
MM	Cyclophosphamide	Cyclophosphamide	1
MM	Melphalan	Melphalan	1
MM	Pomalidomide	Pomalidomide	1
MM	Lenalidomide	Lenalidomide	1
MM	Dexamethasone	Dexamethasone	1
MM	Prednisone	Prednisone	1
MM	Selinexor	Selinexor	1
MM	Venetoclax	Venetoclax	1
MM	RVD	Lenalidomide, Bortezomib, Dexamethasone	2
MM	CyBorD	Cyclophosphamide, Bortezomib, Dexamethasone	2

MM	KRD	Carfilzomib, Lenalidomide, Dexamethasone	2
MM	Ixazomib/Cy/Dex	Ixazomib, Cyclophosphamide, Dexamethasone	1
MM	VTD	Bortezomib, Thalidomide, Dexamethasone	2
MM	Cy/R/D	Cyclophosphamide, Lenalidomide, Dexamethasone	1
MM	Dara/Cy/V/D	Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone	2
MM	Dara/VTD	Daratumumab, Bortezomib, Thalidomide, Dexamethasone	2
MM	V(T)D-PACE	Bortezomib, Dexamethasone, Platinum (Cisplatin OR Carboplatin), Doxorubicin, Cyclophosphamide, Etoposide OR Bortezomib, Thalidomide, Dexamethasone, Platinum (Cisplatin OR Carboplatin), Doxorubicin, Cyclophosphamide, Etoposide	3
MM	Dara/RD	Daratumumab, Lenalidomide, Dexamethasone	2
MM	Rd	Lenalidomide, Dexamethasone	1
MM	Vd	Bortezomib, Dexamethasone	2
MM	Kd	Carfilzomib, Dexamethasone	2
MM	KCyD	Carfilzomib, Cyclophosphamide, Dexamethasone	2
MM	Ixa/Pom/Dex	Ixazomib, Pomalidomide, Dexamethasone	1
MM	Ixa/RD	Ixazomib, Lenalidomide, Dexamethasone	1
MM	Pom/VD	Pomalidomide, Bortezomib, Dexamethasone	2
MM	Elo/VD	Elotuzumab, Bortezomib, Dexamethasone	2

MM	EloRD	Elotuzumab, Lenalidomide, Dexamethasone	2
MM	Elo/Pom/Dex	Elotuzumab, Pomalidomide, Dexamethasone	2
MM	Panobinostat/VD	Panobinostat, Bortezomib, Dexamethasone	2
MM	Seli/VD	Selinexor, Bortezomib, Dexamethasone	2
MM	Bendamustine	Bendamustine	2
MM	Dara monotherapy	Daratumumab monotherapy	2
MM	DCEP	Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin	3
MM	SeliDex	Selinexor, Dexamethasone	1
MM	VenDex	Venetoclax, Dexamethasone	1
MM	Seli/dara/dex	Selinexor, Daratumumab, Dexamethasone	2
MM	Seli/pom/dex	Selinexor, Pomalidomide, Dexamethasone	1

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma.

eTable 2. ARIMA Model Parameters, $(p,d,q)(P,D,Q)_m$

	Overall	AML	DLBCL	FL	MCL	CLL	MM
OralTx	$(2,1,2)(0,1,0)_{12}$	$(1,0,2)(0,1,0)_{12}$	$(0,1,1)(0,1,1)_{12}$	$(2,1,1)(1,1,0)_{12}$	$(1,0,1)(0,1,0)_{12}$	$(0,1,1)(0,1,0)_{12}$	$(2,0,3)(0,1,0)_{12}$
OutPtTx	$(2,1,0)(0,1,0)_{12}$	NA	$(0,1,0)(0,1,0)_{12}$	$(2,1,0)(0,1,0)_{12}$	$(0,1,1)(0,1,1)_{12}$	$(0,1,2)(0,1,0)_{12}$	$(3,1,2)(0,1,0)_{12}$
InPtTx	$(0,1,1)(0,1,1)_{12}$	$(0,1,1)(0,1,0)_{12}$	$(2,1,1)(0,1,0)_{12}$	$(0,1,0)(0,1,1)_{12}$	$(0,1,0)(1,1,0)_{12}$	NA	$(0,1,1)(0,1,1)_{12}$

Notes:
p and P are the non-seasonal and seasonal orders of autoregression (number of lagged observations);
d and D are the non-seasonal and seasonal orders of differencing;
q and Q are the non-seasonal and seasonal moving average orders (number of lagged errors);
m is the number of periods in a season (equal to 12 for monthly data);
NA indicates that no models were run for AML OutPtTx and CLL InPtTx patients.

Abbreviations: AML, acute myeloid leukemia; ARIMA, autoregressive integrated moving average; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma.

eTable 3. Q Statistics and *P* Values for All Ljung-Box Q Tests of the Autocorrelation of ARIMA Model Residuals

	OralTx		OutPtTx		InPtTx	
	Q-statistic	**P-value**	**Q-statistic**	**P-value**	**Q-statistic**	**P-value**
Overall	8.9	0.18	5.3	0.73	7.6	0.47
AML	7.1	0.41	NA	NA	5.1	0.83
DLBCL	4.4	0.82	11	0.34	7.3	0.40
FL	6.4	0.38	15	0.70	7.9	0.54
MCL	9.7	0.28	5.4	0.71	10	0.32
CLL	8.7	0.46	7.7	0.46	NA	NA
MM	14	0.14	7.2	0.21	7.8	0.45

Abbreviations: AML, acute myeloid leukemia; ARIMA, autoregressive integrated moving average; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma.

eTable 4. Percent Change in In-Person Visit Rates Across Entire Pandemic Year (March 1, 2020, to February 28, 2021)

Treatment Type	Overall, % (95% PI)	AML, % (95% PI)	CLL, % (95% PI)	DLBCL, % (95% PI)	FL, % (95% PI)	MCL, % (95% PI)	MM, % (95% PI)
OralTx	-14.4 (-27.2 to 3.7)	-15.3 (-42.1 to 58.0)	-7.3 (-24.5 to 20.0)	-37.4 (-74.8 to >100)	-12.5 (-56.1 to >100)	-9.3 (-36.5 to 58.6)	-15.7 (-26.2 to -1.5)
OutPtTx	-2.6 (-12.4 to 9.6)	NA	-4.0 (-22.3 to 25.7)	7.5 (-38.0 to >100)	6.4 (-24.1 to 78.2)	-1.0 (-18.4 to 25.8)	-1.7 (-9.3 to 7.2)
InPtTx	-0.8 (-14.7 to 18.7)	-6.1 (-18.7 to 11.1)	NA	11.4 (-26.0 to >100)	30.3 (-45.5 to >100)	-12.9 (-47.3 to >100)	-18.9 (-43.8 to 45.3%)

Notes:
Percentage change is calculated as [average actual in-person visit rates − average predicted in-person visit rates] / [average predicted in-person visit rates];
Positive percentages indicate an increase in in-person visit rates during the pandemic;
Negative percentages indicate a decrease in in-person visit rates during the pandemic.

AML OutPtTx and CLL InPtTx are both represented as NA as these disease-treatment types were not represented.

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; Tx, treatment.

eTable 5. In-Person Visit Rates in Year Before vs During Pandemic Over All Diseases Combined and by Disease and Treatment Type

Disease	Treatment Type	1 Year Before pandemic (March 1, 2019-February 28, 2020)	During Pandemic (March 1, 2020-February 28, 2021)
Overall	OralTx	1.26	1.07
	OutPtTx	1.84	1.70
	InPtTx	3.62	3.19
AML	OralTx	4.17	3.49
	InPtTx	5.09	4.57
CLL	OralTx	0.96	0.87
	OutPtTx	1.12	1.05
DLBCL	OralTx	1.75	1.26
	OutPtTx	1.18	1.03
	InPtTx	1.90	1.66
FL	OralTx	0.91	0.89
	OutPtTx	1.21	1.09
	InPtTx	1.39	1.22
MCL	OralTx	1.29	1.18
	OutPtTx	1.71	1.50
	InPtTx	2.54	2.22

MM	OralTx	1.39	1.13
	OutPtTx	3.07	2.87
	InPtTx	1.78	1.60

Note: The following disease-treatment type combinations do not exist and thus are excluded from this table: AML-OutPtTx and CLL-InPtTx.

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma.

eTable 6. Telemedicine Visit Rates During Early vs Later Pandemic Months Over All Diseases Combined and by Disease and Treatment Type

Disease	Treatment Type	Early Pandemic (March 1, 2020-May 31, 2020)	Late Pandemic (June 1, 2020-February 28, 2021)
Overall	OralTx	0.11	0.06
	OutPtTx	0.07	0.05
	InPtTx	0.10	0.06
AML	OralTx	0.14	0.13
	InPtTx	0.11	0.07
CLL	OralTx	0.09	0.05
	OutPtTx	0.06	0.04
DLBCL	OralTx	0.11	0.13
	OutPtTx	0.06	0.04
	InPtTx	0.10	0.05
FL	OralTx	0.28	0.16
	OutPtTx	0.06	0.04
	InPtTx	0.07	0.03
MCL	OralTx	0.13	0.07
	OutPtTx	0.07	0.03
	InPtTx	0.05	0.05

MM	OralTx	0.12	0.07
	OutPtTx	0.09	0.06
	InPtTx	0.10	0.05

Note: The following disease-treatment type combinations do not exist and thus are excluded from this table: AML-OutPtTx and CLL-InPtTx.

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma.